Literature DB >> 18284419

Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.

Suellen N Villena1, Roberta O Pinheiro, Carla S Pinheiro, Marise P Nunes, Cristina M Takiya, George A DosReis, José O Previato, Lucia Mendonça-Previato, Célio G Freire-de-Lima.   

Abstract

The effects of capsular polysaccharides, galactoxylomannan (GalXM) and glucuronoxylomannan (GXM), from acapsular (GXM negative) and encapsulate strains of Cryptococcus neoformans were investigated in RAW 264.7 and peritoneal macrophages. Here, we demonstrate that GalXM and GXM induced different cytokines profiles in RAW 264.7 macrophages. GalXM induced production of TNF-alpha, NO and iNOS expression, while GXM predominantly induced TGF-beta secretion. Both GalXM and GXM induced early morphological changes identified as autophagy and late macrophages apoptosis mediated by Fas/FasL interaction, a previously unidentified mechanism of virulence. GalXM was more potent than GXM at induction of Fas/FasL expression and apoptosis on macrophages in vitro and in vivo. These findings uncover a mechanism by which capsular polysaccharides from C. neoformans might compromise host immune responses.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284419     DOI: 10.1111/j.1462-5822.2008.01125.x

Source DB:  PubMed          Journal:  Cell Microbiol        ISSN: 1462-5814            Impact factor:   3.715


  52 in total

1.  Capsular Material of Cryptococcus neoformans: Virulence and Much More.

Authors:  A Vecchiarelli; C Monari
Journal:  Mycopathologia       Date:  2012-02-08       Impact factor: 2.574

2.  Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles.

Authors:  Ruhi V Ubale; Rikhav P Gala; Susu M Zughaier; Martin J D'Souza
Journal:  AAPS J       Date:  2014-07-01       Impact factor: 4.009

3.  Coinfection with Cryptococcus gattii and Mycobacterium tuberculosis in an otherwise healthy 18-year-old woman.

Authors:  Lindsay Van Tongeren; Tawimas Shaipanich; John A Fleetham
Journal:  Can Respir J       Date:  2011 Jul-Aug       Impact factor: 2.409

Review 4.  The intracellular life of Cryptococcus neoformans.

Authors:  Carolina Coelho; Anamelia L Bocca; Arturo Casadevall
Journal:  Annu Rev Pathol       Date:  2013-09-16       Impact factor: 23.472

5.  Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis.

Authors:  Siu-Kei Chow; Arturo Casadevall
Journal:  Vaccine       Date:  2011-01-14       Impact factor: 3.641

6.  Extracellular vesicles from Cryptococcus neoformans modulate macrophage functions.

Authors:  Débora L Oliveira; Célio G Freire-de-Lima; Joshua D Nosanchuk; Arturo Casadevall; Marcio L Rodrigues; Leonardo Nimrichter
Journal:  Infect Immun       Date:  2010-02-09       Impact factor: 3.441

7.  Modulation of Macrophage Inflammatory Nuclear Factor κB (NF-κB) Signaling by Intracellular Cryptococcus neoformans.

Authors:  James B Hayes; Linda M Sircy; Lauren E Heusinkveld; Wandi Ding; Rachel N Leander; Erin E McClelland; David E Nelson
Journal:  J Biol Chem       Date:  2016-05-26       Impact factor: 5.157

8.  Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan.

Authors:  Magdia De Jesus; André Moraes Nicola; Marcio L Rodrigues; Guilhem Janbon; Arturo Casadevall
Journal:  Eukaryot Cell       Date:  2008-10-24

9.  Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage.

Authors:  Eva Pericolini; Elena Gabrielli; Giovanni Bistoni; Elio Cenci; Stefano Perito; Siu-Kei Chow; Francesca Riuzzi; Rosario Donato; Arturo Casadevall; Anna Vecchiarelli
Journal:  PLoS One       Date:  2010-09-14       Impact factor: 3.240

Review 10.  The capsule of the fungal pathogen Cryptococcus neoformans.

Authors:  Oscar Zaragoza; Marcio L Rodrigues; Magdia De Jesus; Susana Frases; Ekaterina Dadachova; Arturo Casadevall
Journal:  Adv Appl Microbiol       Date:  2009       Impact factor: 5.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.